A failure of Lipocine Inc.'s Tlando (testosterone undecanoate) to meet any of its three pre-specified maximal serum testosterone concentrations (Cmax) secondary endpoints highlights a series of issues the testosterone replacement therapy will have to overcome in front of a US FDA panel in its quest for approval.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?